NC-LINDY-BIOSCIENCES
Lindy Biosciences, a pioneering biotechnology company specializing in innovative drug formulation and delivery technologies, today announced a multi-target exclusive global licensing agreement and strategic collaboration with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS), an innovative medicines company.
The collaboration will focus on transitioning select innovative medicines from the Novartis portfolio to convenient, self-administered subcutaneous injections using Lindy Biosciences’ proprietary microglassification suspension technology. By delivering high concentrations of biologics, this technology significantly increases the maximum dose that can be administered in a single subcutaneous injection. This has the potential to reduce healthcare costs while also improving patient comfort, convenience, and treatment compliance.
Currently, over half of all antibody therapeutics are administered intravenously in a clinical setting, primarily due to the high doses required that cannot be formulated in volumes suitable for subcutaneous injection. Lindy Biosciences’ proprietary microglassification platform technology is poised to transform this paradigm by enabling self-administration at home via pre-filled syringes or autoinjectors.
Strategic Impact and Future Outlook
Dr. Deborah Bitterfield, founder and CEO of Lindy Biosciences, expressed enthusiasm about the collaboration: "We're excited to deepen our collaboration with Novartis. This collaboration is a testament to our shared dedication to enhancing patient care and marks a significant milestone as we take Lindy’s formulation technology into the clinic for the first time. Together, we aim to transform drug delivery and improve treatment access for patients worldwide."
The agreement's financial terms include an upfront payment of US$20 million to Lindy Biosciences. Lindy Biosciences is also eligible to receive up to US$934 million in additional payments across multiple targets upon achieving certain regulatory, development and commercial milestones as well as tiered single-digit royalties on net sales.
This collaboration marks a significant step forward in addressing the growing need for patient-friendly treatment options that can be self-administered at home. By combining innovative technology from Lindy Biosciences and the global reach and expertise of Novartis, the collaboration promises to usher in a new era of drug delivery, reshaping patient care on a global scale.
About Lindy Biosciences
Lindy Biosciences is dedicated to transforming the delivery of biologic drugs and improving patients' lives through innovative biotherapeutic formulations. Our cutting-edge solutions are designed to enhance drug formulation and delivery, specializing in the subcutaneous administration of concentrated (>400 mg/mL) biologic suspensions.
Founded in 2016 and headquartered in Morrisville, NC, Lindy Biosciences leverages core microglassification technology originated at Duke University and further developed by the company. We are committed to partnering with leading pharmaceutical companies to advance treatment accessibility for patients worldwide.
For more information, visit us at www.lindybio.com or follow us on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827920051/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cabot Properties Expands European Leadership Team to Capitalize on Increasingly Attractive Logistics Property Market14.1.2025 18:07:00 CET | Press release
Thomas Schellhorn joins firm as Vice President, Asset Management in Germany; Justin Harvey, Managing Director, Head of UK and Europe, to relocate to London Cabot Properties, a leading investor, developer and operator of logistics properties throughout the United States, Europe and Asia Pacific, today announced that it has expanded its European leadership team as it continues to grow its presence across the region. The firm has hired Thomas Schellhorn as Vice President to oversee asset management for Cabot’s operations in Germany and the Netherlands. In this role, he will be responsible for leasing and capital improvement programs and will report to Jed Raymond, Senior Director and Head of Asset Management for UK and Europe. Justin Harvey, Managing Director and Head of UK and Europe, will relocate to Cabot’s London office to continue leading the firm’s overall strategy and operations across Europe. This press release features multimedia. View the full release here: https://www.businessw
Verimatrix Announces Release of DVB ReAccess Over-the-Air CAS Retrofit Solution14.1.2025 17:45:00 CET | Press release
Verimatrix DVB Access completes Cartesian’s Farncombe Security® Audit Regulatory News: Verimatrix, (Euronext Paris: VMX, FR0010291245), the leader in powering the modern connected world with people-centered security, today announced general availability of its new DVB ReAccess solutions that serves as a uniquely powerful over-the-air (OTA) Conditional Access System (CAS). The solution also provides users with added peace of mind following the recent completion of Cartesian’s Farncombe Security® Audit. DVB ReAccess addresses a notable hurdle for one-way networks such as broadcast satellite providers that lack bidirectional handshakes to identify and authenticate client devices authorized to decrypt content. In one-way networks, the security of content relies almost exclusively on the resistance and resilience of the CAS, the most secure of which have a client software deeply anchored within the device’s hardware, leveraging a number of security features provided by the chipset. Conseque
Kymeta Welcomes Industry Leaders to Board of Advisors14.1.2025 17:00:00 CET | Press release
The world-leading flat-panel satellite antenna company, Kymeta (www.kymetacorp.com) announced today the addition of two new members to the Board of Advisors, James Geurts and Elizabeth Kimber. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114298718/en/ (Graphic: Business Wire) The Honorable James Geurts, known to most as Hondo, has over three decades of leadership in the national security sector, including service as the Under Secretary of the Navy, the Department’s second-highest-ranking civilian, responsible for the effective global business operations of the U.S. Navy and Marine Corps team. From 2017 until 2021, after his Presidential Appointment and unanimous Senate confirmation, he served as the Assistant Secretary of the Navy for Research, Development and Acquisition. Since his retirement from government, Geurts has worked extensively to improve the Nation’s defense industrial base and mentors public and private se
Dfns Secures $16M to Expand its Crypto Wallet Infrastructure for Finance14.1.2025 16:00:00 CET | Press release
Dfns, the leading wallet-as-a-service platform for crypto assets, has successfully closed a $16 million Series A, led by Further Ventures, the venture arm of Abu Dhabi’s largest sovereign wealth fund, ADQ. This round also saw participation from historic investors such as White Star Capital, Hashed, Semantic, Techstars, and Bpifrance, alongside new backers including Motive Partners, Wintermute, and Motier Ventures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250114288142/en/ (Photo: Business Wire) Our Institutional Focus Paid Off Two years ago, Dfns made a strategic up-market move focusing mainly on institutional clients. The company’s vision has remained steadfast: institutional investors hold the key to driving crypto adoption as they have the lion’s share of the global liquidity. To appeal to them, Dfns prioritized uncompromising bank-grade security, aligning with standard traditional financial systems and leveraging st
illumynt, a CNE Direct Company, Announces the Promotion of Jörg Herbarth to COO14.1.2025 16:00:00 CET | Press release
illumynt, a CNE Direct company, is pleased to announce the promotion of Jörg Herbarth to Chief Operating Officer (COO). Jörg joined illumynt in June 2022 and has held several executive roles within the organization. In his new role Jörg will be focusing on solidifying illumynt's position as the market leader in IT Asset Disposition services for the AI and compute sector. He will also lead efforts to expand illumynt's global reverse supply chain solutions for OEMs. With a customer-centric approach, Jörg will drive illumynt's strategic initiatives leveraging data and process automation, powered by AI, to maximize sustainability, security, and value for our clients. We welcome Jörg’s leadership as we continue to innovate and deliver exceptional solutions to our partners and customers worldwide. View source version on businesswire.com: https://www.businesswire.com/news/home/20250113438203/en/
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom